Bronchodilator Effects of Nebulized Versus Inhaled Albuterol in Women With Lymphangioleiomyomatosis

What this Trial Is About

Researchers are evaluating the effects of two methods of delivering albuterol, a bronchodilator, to improve lung function in women with lymphangioleiomyomatosis (LAM), a rare lung disease characterized by muscle tissue growth that blocks airflow. This progressive condition mainly affects women and can lead to severe breathing problems, sometimes requiring lung transplantation. The study aims to determine whether inhaled albuterol given by a nebulizer or a metered dose inhaler (MDI) better improves lung function in affected women. Participants will receive albuterol either by nebulizer or by inhaler, with doses given once daily for three consecutive days during a 3-day overnight stay at the National Institutes of Health. Those using long-acting inhalers will stop these medications one week before the study. Treatments include either nebulized albuterol or two to four puffs of the inhaler, with four puffs representing a higher dose than usual. Lung function tests are performed before and after each treatment to assess the effects. During the study, participants undergo screening involving a physical exam and medical history review. Lung function tests are conducted daily before and after albuterol administration. The main outcome measured is the improvement in lung function over the three days, comparing the two delivery methods. Safety and tolerability are monitored throughout the study, which is expected to last until November 2027.

Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis